Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McKinsey Sees Indian Drug Industry at US$20bn By 2015 (India)

This article was originally published in PharmAsia News

Executive Summary

Global consulting firm McKinsey forecasts the Indian pharmaceutical market tripling by 2015, from the current $6.5 billion to $20 billion. According to McKinsey's latest report, titled, "India Pharma 2015: Unlocking the Potential of the Indian Pharmaceuticals Market," the sector will grow by 12% annually for the next few years. One key driver for the expected market growth in India is the doubling of disposable income and an increase in the number of middle-class households. Several other factors will play a key role in the growth of the pharmaceutical market, including large private sector investments in health infrastructure, an increase in the number of physicians, greater penetration of health insurance, the rising prevalence of chronic diseases, and aggressive market penetration by smaller companies. However, concerns over drug pricing policies and product patent regulations could threaten the expected growth. McKinsey's report suggests that while the present generics industry will continue to dominate the Indian pharmaceutical market, patented products will constitute close to 10 percent of the market in the next ten years. (Click here for more

You may also be interested in...

PharmAsia News Notable Notes: Deutsche Bank Report Bullish on Indian Market

A new study has predicted that drug sales in India will rise 8 percent annually over the next few years compared to 6 percent growth worldwide. The report by Deutsche Bank says drug sales would reach €20 billion ($31 billion) by 2015

Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts